Clinical manifestations of ocular toxoplasmosis

Ocular Immunology and Inflammation

Volumn 19, Issue 2, 2011, Pages 91-102

  Delair, Emmanuelle ^a   Latkany, Paul ^b   Noble, A Gwendolyn ^c   Rabiah, Peter ^d   McLeod, Rima ^e   Brézin, Antoine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NEW YORK UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

CNVM; congenital toxoplasmosis; r tinal choriditis; Toxoplasma gondii; uveitis

Indexed keywords

SULFAMETHOXAZOLE; TRIMETHOPRIM;

ARTICLE; CATARACT; CHORIORETINITIS; CLINICAL FEATURE; CONGENITAL TOXOPLASMOSIS; DISEASE COURSE; DISEASE SEVERITY; EPIRETINAL MEMBRANE; EYE DISEASE; EYE EXAMINATION; FLUORESCENCE ANGIOGRAPHY; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; IRIDOCYCLITIS; OPTIC NERVE DISEASE; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PHLEBITIS; RECURRENT DISEASE; RETINA BLOOD VESSEL OCCLUSION; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA VASCULITIS; SCOTOMA; SEROLOGY; SUBRETINAL NEOVASCULARIZATION; TOXOPLASMA GONDII; TOXOPLASMOSIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRITIS;

BRAZIL; CATARACT; CHOROIDITIS; CICATRIX; EYE DISEASES; HUMANS; INFLAMMATION; OPTIC NERVE DISEASES; RECURRENCE; RETINAL DISEASES; TOXOPLASMOSIS, OCULAR; UNITED STATES; UVEITIS, ANTERIOR; VISION DISORDERS; VITREOUS BODY;

EID: 79953077653     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2011.564068     Document Type: Article

References (58)

1. Hogan MJ, Kimura SJ, Lewis A, et al. Early and delayed ocular manifestations of congenital toxoplasmosis. Trans Am Ophthalmol Soc 1957; 55: 275-296.
2. Mets MB, Holfels E, Boyer KM, et al. Eye manifestations of congenital toxoplasmosis. Am J Opthalmol. 1996; 122: 309-324. (Pubitemid 26300047)
3. O'Connor GR. Manifestations and management of ocular toxoplasmosis. Bull N Y Acad Med. 1974; 50: 192-210.
4. McLeod R, Boyer K, Karrison T, et al. Outcomes of treat-ment of congenital toxoplasmosis,1981-2004,The National Collaborative Chicago-based Congenital Toxoplasmosis Study (NCCCTS). CID. 2006a; 42: 1383-1394.
5. McAuley J, Roizen N, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated his-torical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin Inf Dis. 1994; 18: 38-72. (Pubitemid 24025917)
6. McLeod R, Mack D, Foss R, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fuids from infants treated for congenital toxoplasmosis. Antimicrob Ag Chemother. 1992; 36: 1040-1048.
7. Rothova A. Ocular involvement in toxoplasmosis. Br J Ophthalmol. 1993; 77: 371-377. (Pubitemid 23193386)
8. Roizen N, Kasza K, Karrison T, et al. Impact of visual impairment on measures of cognitive function for chil-dren with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006; 118: e379-e390. (Pubitemid 46090508)
9. Roberts F, Mets MB, Ferguson DJ, et al. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch Ophthalmol. 2001; 119: 51-58. (Pubitemid 32096385)
10. McLeod R, Kieffer F, Sautter M, et al. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009 Mar; 104(2): 320-344.
11. Dodds EM, Holland GN, Stanford MR, et al. Intraocular infammation associated with ocular toxoplasmosis: relationships at initial examination. Am J Ophthalmol. 2008 Dec;146(6):856-865.
12. Arun V, Noble AG, and the Toxoplasmosis Study Group. Cataracts in congenital toxoplasmosis. J. Am Assoc Pediatr Ophthalmol Strabismus. 2007 December; 11: 551-554. (Pubitemid 350251240)
13. Song A, Scott IU, Davis JL, et al. Atypical anterior optic neuropathy caused by toxoplasmosis. Am J Ophthalmol. 2002;133:162-164. (Pubitemid 34076527)
14. Gaynon MW, Boldrey EE, Strahlman ER, et al. Retinal neovascularisation and ocular toxoplasmosis. Am J Ophthalmol. 1984; 98: 585-589.
15. Fine SL, Owens SL, Haller JA, et al. Choroidal neovascularisation as a late complication of ocular toxoplasmosis. Am J Ophthalmol. 1981; 91: 318-322. (Pubitemid 11147119)
16. Benevento JD, Jager RD, Noble AG, et al. Toxoplasmosisassociated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy Arch Ophthalmol. 2008 Aug; 126(8): 1152-1156.
17. Ben Yahia S, Herbort CP, Jenzeri S, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol. 2008 Aug; 28(4): 311-316.
18. Gentile RC, Berinstein DM, Oppenheim R, Walsh JB. Retinal vascular occlusions complicating acute toxoplasmic retinochoroiditis. Can J Ophthalmol. 1997; 32: 354-358. (Pubitemid 27394796)
19. Pakalin S, Arnaud B. Arterial occlusion associated with toxoplasmic chorioretinitis. J Fr Ophtalmol. 1990; 13: 554-556.
20. Williamson TH, Meyer PA. Branch retinal artery occlusion in toxoplasma retinochoroiditis. Br J Ophthalmol. 1991; 75: 253.
21. Adan A, Giralt J, Alvarez G, Alforja S, et al. Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. Eur J Ophthalmol. 2009; 19: 1039-1043.
22. Bosch-Driessen LH, Karimi S, Stilma JS, et al. Retinal detachment in ocular toxoplasmosis. Ophthalmology. 2000; 107: 36-40. (Pubitemid 30210179)
23. Frau E, Gregoire-Cassoux N, Lautier-Frau M, et al. Choriorétinites toxoplamiques compliquées de décollement de rétine. J Fr Ophtalmol. 1997; 10: 749-752. (Pubitemid 28051882)
24. Boyer, K, Roizen N, Rabiah P, et al. The child with congenital toxoplasmosis. In: Remington JS, ed. Current Clinical Topics in Infectious Diseases. Blackwell Science Inc.; Boston MA 2000:189-207
25. Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology. 2008 Mar; 115(3): 553-559.
26. Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the frst year of life. Am J Ophthalmol. 2008 Sep; 146(3): 375-384.
27. Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med. 1994; 330: 1858-1863. (Pubitemid 24188138)
28. Vasconcelos-Santos DV, Machado Azevedo DO, Campos WR, et al. Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology. 2009; 116(11): 2199-205.e1.
29. Brézin AP, Thulliez P, Couvreur J, et al. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol. 2003; 35: 779-784. (Pubitemid 36677394)
30. Kieffer F, Wallon M, Garcia P, et al. Risk factors for retinochoroiditis during the frst 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J. 2008; 27: 27-32.
31. Kodjikian L, Wallon, Fleury M, et al. Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophthalmol. 2006; 244: 14-21. (Pubitemid 43013177)
32. Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr. 1989; 115: 765-769. (Pubitemid 19270273)
33. Peyron F, Wallon M, Bernardoux C. Long-term follow-up of patients with congenital ocular toxoplasmosis [letter]. N Engl J Med. 1996; 334: 993-994. (Pubitemid 26114174)
34. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. 2004; 113: 1567-1572. (Pubitemid 38697960)
35. Cortina-Borja M, Tan HK, Wallon M, et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study PLoS Med. 2010; 7(10). pii: e1000351.
36. Caffos F, Forestier F, Capella-Pavlovsky M, et. al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med. 1988; 318: 271-275. (Pubitemid 18034517)
37. Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol. 1999; 180: 410-415. (Pubitemid 29093877)
38. Binquet C, Wallon M, Quantin C, et al. Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect. 2003; 131: 1157-1168. (Pubitemid 38195591)
39. Bloch-Michel, Etienne. Ocular toxoplasmosis: clinical aspect. Int Ophthalmol. 1990; 14: 353-357.
40. Couvreur J, Desmonts G, Aron-Rosa D. Le prognostic oculare de la toxoplasmose congenitale: role du traitement. Ann Pediatr. 1984; 31: 855-858. (Pubitemid 15176503)
41. Couvreur J, Desmonts G, Tournier G. Etude d'une serie homogene de 210 cas de toxoplasmose congénitale chez des nourrissons ages de 0 à 11 mois et depistes de facon prospective. Sem Hop Paris. 1985; 61: 3015-3019. (Pubitemid 16256542)
42. [In utero treatment of congenital toxoplasmosis with a pyrimethamine-sulfadiazine combination.] Presse Med. 1991; 20: 1137.
43. Couvreur J, Thulliez P, Daffos F, et al. In utero treatment of toxoplasmic fetopathy with the combination pyrimethaminesulfadiazine. Fetal Diagn Ther. 1993; 8: 45-50. (Pubitemid 23085593)
44. Desmonts G. Acquired toxoplasmosis in pregnant women evaluation of the frequency of transmission of Toxoplasma and of congenital toxoplasmosis. Lyon Med. 1982; 248: 115-123. (Pubitemid 13222920)
45. Thulliez P. Commentary: effcacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out. Int J Epidemiol. 2001; 30:1315-1316. (Pubitemid 34134281)
46. Röser D, Nielsen HV, Petersen E, et., al. Congenital toxoplasmosis-a report on the Danish neonatal screening programme 1999-2007. J Inherit Metab Dis. 2010; 33(Suppl 2): S241-S247.
47. Glasner P, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992; 114: 136-144.
48. Ronday M, Luyendijk L, Baarsma S, et al. Presumed acquired ocular toxoplasmosis. Arch Ophthalmol. 1995; 113: 1524-1529.
49. Bosch-Driessen E, Rothova A. Recurrent ocular disease in postnatally acquired toxoplasmosis. Am J Ophthalmol. 1999; 128: 421-425. (Pubitemid 29479316)
50. Delair E, Monnet D, Grabar S, Dupouy-Camet J, et al. Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am J Ophthalmol. 2008 Dec; 146(6): 851-855.
51. Holland G, Muccioli C, Silveira C, et al. Intraocular infam-matory reactions without focal necrotizing retinochoroidi-tis in patients with acquired systemic toxoplasmosis. Am J Ophthalmol. 1999;128:413-420 (Pubitemid 29479315)
52. Noble, AG, Latkany P, Kusmierczyk, et al. Chorioretinal lesions in mothers of children with congenital toxoplasmo-sis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Sci Med. 2010 20(1):20-26.
53. Koppe JG, Kloosterman GJ. Congenital toxoplasmosis: long-term follow-up. Padiatr Padol. 1982; 17: 171-179. (Pubitemid 12048991)
54. Koppe JG, Loewer-Sieger DH, DeRoever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986; 1: 254-256. (Pubitemid 16132862)
55. Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, et al. Ocular toxoplasmosis: clinical features and prog-nosis of 154 patients. Ophthalmology. 2002 May; 109(5): 869-878. (Pubitemid 34465218)
56. Holland GN, Crespi CM, ten Dam-van Loon N, et al. Analysis of recurrence patterns associated with toxoplas-mic retinochoroiditis. Am J Ophthalmol. 2008 Jun; 145(6): 1007-1013.
57. Silveira C, Belfort R Jr, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treat-ment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002; 134: 41-46. (Pubitemid 34722708)
58. Jamieson SE, de Roubaix LA, Cortina-Borja M, et al. Genetic and epigenetic factors at COL2A1 and ABCA4 infuence clini-cal outcome in congenital toxoplasmosis.PLoS ONE. 2008; 3: e2285.